Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
Conditions
Brief summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Detailed description
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.
Interventions
DIAGNOSTIC_TESTT-TAS
Blood test, laboratory assays
Sponsors
Sahlgrenska University Hospital
Region Stockholm
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with decompensated liver cirrhosis * 18 years or older. * Healthy individuals 18 years or older will serve as controls.
Exclusion criteria
* • Extrahepatic malignancy or recurrence of such within the last year. * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion. * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies * Previous liver transplantation. * Transfusions the last 7 days. * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differences in laboratory values between groupstests | up to 5 years | Laboratory values of novel hemostasis tests TTAS, Quantra and OHP correlated to Rotem, TG and conventional coagulation assays. All tests have differnet values. |
| Correlation between systemic inflammation and hemostasis measured by novel assays | uo to 7 years | Correlation between systemic inflammation measured by cytokines, NETs and ECV and hemostasis measured by novel assays as in outcome 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participant with bleeding | Up to 7 years | Bleeding defined according to ISTH |
| Number of participants with Thrombosis | Up to 7 years | Splanchnic or non-splanchnic thrombosis |
| Number of participants that die | Up to 7 years | — |
| Number of participant going to transplant | Up to 7 years | Number of patients getting a transplant, acute, subacute or according to waiting list |
Countries
Sweden
Contacts
Primary ContactSanna Norén, MD, PhDstudent
Backup ContactMaria Magnusson, MD, PhD
Outcome results
None listed